ORIGINAL INVESTIGATION. Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease
|
|
- Edwin Hunt
- 6 years ago
- Views:
Transcription
1 Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease The Framingham Study ORIGINAL INVESTIGATION Zaldy Sy Tan, MD, MPH; Sudha Seshadri, MD; Alexa Beiser, PhD; Peter W. F. Wilson, MD; Douglas P. Kiel, MD, MPH; Michael Tocco, BA; Ralph B. D Agostino, PhD; Philip A. Wolf, MD Background: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 ( ) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. Results: Alzheimer disease developed in 77 subjects from 1992 to After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, ) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95% confidence interval, ). Conclusion: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD. Arch Intern Med. 2003;163: From the Division on Aging, Harvard Medical School (Drs Tan and Kiel), the Departments of Neurology (Drs Seshadri and Wolf and Mr Tocco) and Medicine (Dr Wilson), Boston University School of Medicine, the Department of Epidemiology and Biostatistics, Boston University School of Public Health (Dr Beiser), the Hebrew Rehabilitation Center for Aged Research and Training Institute (Drs Tan and Kiel), and the Department of Mathematics and Statistics, Boston University (Dr D Agostino), Boston, Mass. The authors have no relevant financial interest in this article. THE APOLIPOPROTEIN E (APOE) 4 allele is a cholesterol transport protein that is a well-established risk factor for late-onset Alzheimer disease (AD). 1 The presence of an APOE 4 allele increases the lifetime risk for development of AD and is also associated with an earlier age of onset. However, it is an incomplete predictor of disease susceptibility, as AD does not develop in all subjects with the APOE 4 allele and not all patients with AD have the 4 allele. The underlying pathophysiology that explains the relationship between APOE 4 and AD remains speculative, but may involve an APOE 4 mediated increase in serum cholesterol levels. Cholesterol has been linked to the development of AD by studies showing an association between lipoprotein(a) levels and AD 2 and between low-density lipoprotein receptor related protein and AD 3 and by epidemiological studies implicating cardiovascular risk factors in the development of dementia. 4 Recently, several studies have suggested that the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) to lower cholesterol levels reduces the risk for AD. 5,6 These studies are observational, and results from randomized, clinical trials are not yet available. Several observational epidemiological studies examining the association between cholesterol and AD have yielded conflicting results. 7-9 Possible explanations for the heterogeneity of results from these studies may be the use of single rather than cumulative, time-averaged cholesterol levels, 7,9 the restriction of the study population to men, 8 and the brief follow-up in some studies. 7,9 The Framingham Heart Study data provide an opportunity to examine the association between lifetime cholesterol levels and the risk for development of AD in a large populationbased cohort of men and women during a 25-year follow-up. 1053
2 Table 1. Baseline Subject Characteristics and Cholesterol Levels at Examination Cycle 20 ( )* Men (n = 380) Women (n = 646) Total (N = 1026) Age, y 75.7 (5.2) 76.4 (5.4) 76.1 (5.3) Total cholesterol, (38.4) (36.4) (37.9) mg/dl HDL cholesterol, 41.2 (11.8) 53.5 (16.2) 48.9 (15.8) mg/dl BMI 27.1 (3.9) 26.4 (5.0) 26.7 (4.6) Mean TC (34.2) (33.7) (33.9) TC (30.2) 16.1 (32.3) 15.8 (31.5) APOE genotype, No. (%) 2/ 2, 2/ 3, 297/380 (78.2) 513/646 (79.4) 810/1026 (78.9) 3/ 3 2/ 4, 3/ 4, 83/380 (21.8) 133/646 (20.6) 216/1026 (21.1) 4/ 4 CHD, No. (%) 103/380 (27.1) 99/646 (15.3) 202/1026 (19.7) Diabetes, No. (%) 47/380 (12.4) 52/646 (8.1) 99/1026 (9.7) Smoking 5 pack-years, No. (%) 121/338 (35.8) 374/589 (63.5) 495/927 (53.4) Abbreviations: APOE, apolipoprotein E; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CHD, coronary heart disease; HDL, high-density lipoprotein; TC1-15, total cholesterol levels across biennial examination cycles 1 to 15; TC15-20, change in total cholesterol levels between examination cycles 15 and 20. SI conversion factor: To convert cholesterol to millimoles per liter, multiply by *Unless otherwise indicated, data are expressed as mean (SD). Table 2. Age- and Sex-Adjusted Hazard Ratios of AD in Relation to Cholesterol Measurements AD, No./Study Population METHODS STUDY POPULATION Hazard Ratio (95% Confidence Interval) Mean TC / ( ) TC20 76/ ( ) HDL at examination 20 75/ ( ) TC15-20* 67/ ( ) Abbreviations: AD, Alzheimer disease; TC1-15, total cholesterol levels across examination cycles 1 to 15; TC20, total cholesterol level measured at the 20th examination cycle; TC15-20, change in cholesterol levels from the 15th to the 20th examination cycles. *Includes only those subjects who were not receiving medications to lower lipid levels. The Framingham Study is a longitudinal population-based cohort study of 5209 participants (2336 men and 2873 women) who have undergone evaluation for cardiovascular risk factors since In 1975, at the start of the 14th biennial examination cycle, 3330 subjects from the original cohort were still alive. Of these, 2828 (85%) attended the 14th biennial examination. Of the 2123 subjects undergoing testing using a standardized neuropsychological test battery 10 administered during cycles 14 and 15, 2082 were judged to be cognitively intact. An additional 529 subjects who were not administered the neuropsychological test battery for logistic reasons had normal results of the Folstein Mini-Mental State Examination 11 performed between 1982 and This yielded 2611 subjects (1061 men and 1550 women; mean±sd age, 66±7.4 years; age range, years) who were cognitively intact at examination cycle 14. Subjects suspected of having cognitive impairment on neuropsychological testing underwent evaluation by a neurologist, and 41 subjects who were diagnosed as having dementia or cognitive impairment were excluded. At examination cycle 20, 1229 subjects were alive and free of dementia. Of these, 203 subjects were excluded due to prevalent stroke (n=75) or lack of APOE data (n=128). The remaining 1026 subjects (646 women and 380 men) constituted our study sample. Baseline characteristics of subjects at examination cycle 20 are presented in Table 1 and Table 2. CHOLESTEROL LEVELS During the 40 years of follow-up (examination cycles 1-20), nonfasting cholesterol levels in the Framingham Study subjects were measured at 19 examinations. 13 Nonenzymatic laboratory methods were used until the 20th biennial examination. 14 Plasma cholesterol level was determined according to the Abell-Kendall method, and high-density lipoprotein cholesterol (HDL-C) level was measured after precipitation of plasma with a combination of heparin-manganese. 15,16 Previous studies have shown that in comparing fasting and nonfasting cholesterol measurements, a 6% increase would be found in one third of the population; no change, in one third; and a 7% decrease, in one third, for a negligible population net difference attributable to fasting status. 17 We used the following 3 different measures of total cholesterol level: the mean of the total cholesterol measurements obtained at or before the 15th examination cycle (mean TC1-15) as an estimate of time-averaged cholesterol level in subjects undergoing total cholesterol level estimates at 4 or more examination cycles by cycle 15; the total cholesterol level measured at examination cycle 20 (TC20) as an estimate of baseline cholesterol level; and the change in cholesterol levels between examination cycles 15 and 20 ( TC15-20) as a measure of change in cholesterol levels, excluding subjects taking medications to lower lipid levels (n=83). The TC15-20 was taken as an absolute difference between the cholesterol levels in the 2 examination cycles and treated continuously in the regression. In addition, we examined the relation of HDL-C levels at the 20th biennial examination to the risk for incident AD. APOE GENOTYPES We determined APOE genotypes using an isoelectric focusing of plasma and confirmed the findings by subsequent genotyping. 18,19 Participants were dichotomized into one group consisting of persons with APOE 2/ 2, 2/ 3, or 3/ 3 genotypes, and the other consisting of those with APOE 2/ 4, 3/ 4, or 4/ 4 genotypes. CASE ASCERTAINMENT Beginning at examination cycle 17 (1982), the Mini-Mental State Examination was administered biennially to the cohort. A Mini- Mental State Examination score below the education-specific cutoff score, a decline of 3 or more points between consecutive biennial examinations, or a decline of more than 5 points compared with any previous examination prompted more indepth testing. 20 For each subject with possible dementia, neurological and neuropsychological examinations were performed. Subjects with mild cognitive impairment (Clinical Dementia Rating 21 scale score, 0.5) underwent reassessment at least biennially for progression to moderate or severe dementia. A panel consisting of 2 neurologists and a neuropsycholo- 1054
3 gist reviewed all subjects designated as having significant dementia (Clinical Dementia Rating scale score, 1) by the examining neurologists. We used data from the neurologist s examination, neuropsychological test performance, Framingham Study records, hospital medical records, information from primary care physicians, computed tomographic and magnetic resonance imaging records, and autopsy confirmation when available. All subjects identified as having dementia satisfied the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 22 had dementia severity of at least 1 on the Clinical Dementia Rating scale, and exhibited symptoms of dementia for a period of at least 6 months. All subjects identified as having AD met the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer s Disease and Related Disorders Association 23 for definite, probable, or possible AD. All subjects who were alive and free of dementia and stroke and who attended examination cycle 20 ( ) were followed up longitudinally from examination 20 onward for the development of dementia. Therefore, at least a 10-year interval occurred from the last measurement of cholesterol level at examination 15 to the start of longitudinal follow-up that began at examination 20. This 10-year interval and the baseline screening of all subjects for dementia in 1976 to 1978 significantly increased the probability of effectively screening out subjects with subclinical dementia at the time of estimation of cholesterol level. DEFINITION OF ADDITIONAL RISK FACTORS Risk factors that could potentially confound the relationship between cholesterol level and AD were defined using data collected at the 20th biennial examination. Educational status was dichotomized at the level of high school completion. Cigarette smoking was defined as a lifetime smoking exposure of at least 5 pack-years. Diabetes mellitus was defined as a recorded casual blood glucose level of at least 200 mg/dl ( 11.1 mmol/l), a previous diagnosis of diabetes mellitus, or use of a hypoglycemic agent, including insulin. Systolic blood pressure and body mass index (calculated as weight in kilograms divided by the square of height in meters) were treated as continuous variables. Coronary heart disease was defined to include angina pectoris, myocardial infarction, and coronary insufficiency. 24 STATISTICAL ANALYSIS We used Cox proportional hazards regression analyses to examine the association between each of the various measures of total cholesterol and HDL-C levels and the subsequent development of incident AD, with and without adjustment for potential confounders (age, sex, APOE genotype, coronary heart disease, smoking, therapy to lower lipid levels, diabetes, and body mass index). RESULTS From 1992 to 2000, AD developed in 77 subjects. The baseline characteristics of the subjects are presented in Table 1. We found no significant association between the risk for incident AD (Table 2) and mean TC1-15 or TC20. Adjusting for potential confounders did not change this lack of association between the dependent and independent variables (Table 3) (hazard ratios [HR] per 10- mg/dl [0.3-mmol/L] rise in serum total cholesterol level, 0.95 and 0.97, respectively; 95% confidence intervals [CIs] and , respectively). Table 3. Multivariate Adjusted Hazard Ratios of AD in Relation to Cholesterol Measurements* AD, No./Study Population We also examined the relationship of HDL-C level measured at examination 20 and the risk for AD. No significant association was noted in this cohort (HR, 1.10; 95% CI, ). Likewise, among subjects not receiving medication to lower lipid levels, the TC15-20 was not significantly associated with AD risk (HR, 1.01; 95% CI, ). COMMENT Hazard Ratio (95% Confidence Interval) Mean TC / ( ) TC20 60/ ( ) HDL at examination 20 60/ ( ) TC / ( ) Abbreviations: AD, Alzheimer disease; TC1-15, total cholesterol levels across examination cycles 1 to 15; TC20, total cholesterol level measured at the 20th examination cycle; TC15-20, change in total cholesterol levels between examination cycles 15 and 20. *Adjusted for age, sex, apolipoprotein E genotype, coronary heart disease, therapy to lower lipid levels, and body mass index. Includes subjects who were not receiving medications to lower lipid levels. Epidemiological studies suggest that atherosclerosis is associated with an increased risk for Alzheimer dementia. 4,25 Critical coronary artery disease has been associated with a 3- to 10-fold increased risk for cerebral -amyloid plaques, the neuropathologic hallmark of AD, relative to control subjects free of coronary heart disease. 26 Similarly, an in vivo animal study showed a graded hippocampal accumulation of immunolabeled -amyloid with increasing duration of feeding with a highcholesterol diet. 27 A human postmortem study showed that subjects with neuropathologically diagnosed AD had significantly elevated levels of low-density lipoprotein cholesterol, apolipoprotein B, and brain -amyloid and significantly lower levels of HDL-C compared with controls. 28 A cholesterol-ad link is further suggested by recent epidemiological studies that demonstrate an association between the use of certain agents that lower cholesterol levels (statins) and a decreased risk for dementia. 5,6 This observation appears to support earlier tissue culture studies that show complete inhibition of -amyloid formation in hippocampal cell cultures treated with lovastatin and methyl- -cyclodextrin, suggesting that -amyloid formation is a cholesterol-dependent process. 29 However, the observed protective effect of statins in the epidemiological studies was independent of the presence or absence of hyperlipidemia and was not seen in subjects treated with nonstatin agents to lower lipid levels. Previous prospective epidemiological studies exploring the relationship between serum cholesterol levels and the risk for AD have yielded varying results. A study of survivors of the Finnish cohort of the Seven Countries Study found that a high serum total choles- 1055
4 terol level (mean level, 251 mg/dl [ 6.5 mmol/l]) at 40 to 59 years of age predicted AD in later life. 8 The Finnish and Framingham Study cohorts are both white populations comparable in age and were studied during a similar period. Some differences between the 2 studies are the inclusion of subjects with prevalent dementia and the lack of women in the Finnish cohort. However, in our study population, the inclusion of subjects with prevalent dementia did not change our results (data not presented), and we did not find a sex-specific effect. Other possible explanations include the varying case definitions of dementia in the 2 studies (Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, in the Finnish cohort and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition in the Framingham cohort), the use of fasting rather than nonfasting plasma cholesterol levels in the Finnish cohort, and ethnic variations within white populations. Mean plasma cholesterol levels in Finnish populations are higher than in other ethnic white populations. 30 Romas et al 9 found that subjects with the lowest ( 177 mg/dl [ 4.6 mmol/l]) baseline total cholesterol level had an increased risk for incident dementia after 2.5 years of follow-up. This inverse relationship between cholesterol levels and incident AD may be accounted for by the short follow-up. When the follow-up is short, subjects with subclinical dementia at the start of the study may be erroneously classified as cognitively intact. This is important because, even in the early stages, dementia may cause a decrease in food intake, weight, and plasma cholesterol levels. 31 Moreover, since cholesterol levels decline with age, the age of the subject at the time of cholesterol level determination can be a significant factor, when using single rather than timeaveraged cholesterol levels. 32 Older subjects are more likely to have low plasma cholesterol levels and also a greater risk for development of AD. This may explain why the association observed by Romas et al 9 was no longer significant after adjustment for age. In our study, the 10-year interval between the last cholesterol level (examination 15) and the start of longitudinal follow-up for dementia (examination 20) significantly increased the probability of screening out subclinical dementia. We also used the average of multiple serial cholesterol levels estimated biennially for a 30- year period to achieve a more accurate reflection of lifetime cholesterol levels. Additional strengths of the present study are the ongoing surveillance for incident stroke in the Framingham cohort (thus reducing the chances that subjects with mixed or vascular dementia are inaccurately classified as having AD), long followup, and ability to control for multiple potential confounders. The primarily white American study population limits the applicability of our conclusions to other population groups. The lack of association between TC20, mean TC1-15, or recent TC15-20 and the risk for AD in the Framingham cohort supports the postulate that an alternative explanation exists for the observed association of statin use with a lower risk for AD. In addition to their lipid-lowering activity, statins have other putative beneficial effects, including capillary dilation, increased blood flow, blockage of macrophage and platelet activation, immunosupression, and antiinflammatory actions. These mechanisms, independent of the lowering of lipid levels, are hypothesized to be responsible for some of the beneficial effect of statins on coronary artery disease, renal failure, stroke prevention, and cerebral infarct size reduction A similar mechanism may exist for the relationship between statin use and the risk for Alzheimer dementia. Inflammatory mechanisms involving complement, acute-phase reactants, cytokines, and proteases have been implicated in the pathogenesis of AD. 36 Further studies are warranted to confirm the beneficial effect of statins in the risk for AD and to elucidate the mechanism by which they may exert this effect. CONCLUSIONS Despite plausible biological mechanisms and a remarkable convergence of data linking cholesterol levels to the pathophysiology of and the corresponding risk for AD, our study found that elevated serum total cholesterol level was not a significant risk factor for development of Alzheimer dementia. Accepted for publication July 31, This study was supported by grants 5R01- AG and 5R01-AG from the National Institute of Aging, Bethesda, Md; grant 5R01-NS from the National Institute of Neurological Disorders and Stroke, Bethesda; and contract N01-HC from the National Institutes of Health, Bethesda. Corresponding author and reprints: Philip A. Wolf, MD, Neurological Epidemiology and Genetics Division, Department of Neurology, Boston University School of Medicine, 715 Albany St, Room B-608, Boston, MA ( pawolf@bu.edu). REFERENCES 1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer s disease in late onset families. Science. 1993;261: Mooser V, Helbecque N, Miklossy J, Marcovina SM, Nicod P, Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with lateonset Alzheimer s disease. Ann Intern Med. 2000;132: Hyman BT, Strickland D, Rebeck GW. Role of Low-density lipoprotein receptor related protein in -amyloid metabolism and Alzheimer disease. Arch Neurol. 2000;57: Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer s disease in the Rotterdam Study. Lancet. 1997; 349: Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57: Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356: Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer s disease: a population-based study of African Americans. Neurology. 2000;54: Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E 4 allele, and Alzheimer s disease. Neuroepidemiology. 1998;17: Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 1999;53: Farmer ME, White LR, Kittner SJ, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 1987;60(3, pt 2):
5 11. Folstein ME, Folstein SE, McHugh PR. Mini-Mental State : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer s disease in a general population: the Framingham Study. Neurology. 1993; 43: Wilson PWF, Hoeg JM, D Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337: Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195: Lipid Research Clinics Program. Manual of Laboratory Operation. Bethesda, Md: National Institutes of Health; Publication NIH Warnick GR, Benderson J, Albers JJ. Dextran sulfate Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982; 28: Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements: variations and practical utility. JAMA. 1992;267: Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Shaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoe1 and apoe5 isoforms. J Lipid Res. 1987;28: Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PW, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol. 1998;18: Cobb JL, Wolf PA, Au R, White R, D Agostino RB. The effect of education on the incidence of dementia and Alzheimer s disease in the Framingham Study. Neurology. 1995;45: Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer s disease. Neurology. 1984;34: Cupples LA, D Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung and Blood Institute; NIH publication , section Wilson PW, Shaefer EJ, Larson MG, Ordova JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Aterioscler Thromb Vasc Biol. 1996;16: Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC III. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol. 1993;52: Sparks DL, Scheff SW, Hunsacker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126: Kuo YM, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer s disease correlates with brain A 1-42 levels. Biochem Biophys Res Commun. 1998;252: Simons M, Keller P, DeStrooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of -amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95: Hallman DM, Boerwinkle E, Saha N, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 1991;49: Shatenstein B, Kergoat MJ, Nadon S. Anthropometric changes over 5 years in elderly Canadians by age, gender and cognitive status. J Gerontol A Biol Sci Med Sci. 2001;56:M483-M Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol. 1994;49:M252-M Davignon J, Laaksonen R. Low-density lipoprotein independent effects of statins. Curr Opin Lipidol. 1999;10: Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 101: Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54: McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;5:
The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 7, M414 M418 Copyright 2002 by The Gerontological Society of America The Impact of the Use of Statins on the Prevalence of Dementia and the
More informationORIGINAL CONTRIBUTION. Plasma Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Plasma Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease The Framingham Heart Study Ernst J. Schaefer, MD; Vanina Bongard, MD, PhD; Alexa
More informationORIGINAL CONTRIBUTION. Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
ORIGINAL CONTRIBUTION Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women Kristine Yaffe, MD; Elizabeth Barrett-Connor, MD; Feng Lin, MS; Deborah Grady, MD Background: Few strategies
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationIncidence of Dementia over Three Decades in the Framingham Heart Study
The new england journal of medicine Original Article Incidence of Dementia over Three Decades in the Framingham Heart Study Claudia L. Satizabal, Ph.D., Alexa S. Beiser, Ph.D., Vincent Chouraki, M.D.,
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationHigh Density Lipoprotein Cholesterol and Mortality
High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Statin Use and the Risk of Incident Dementia
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Statin Use and the Risk of Incident Dementia The Cardiovascular Health Study Thomas D. Rea, MD, MPH; John C. Breitner, MD; Bruce M. Psaty, MD, PhD; Annette
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationThe Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults
The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationThe New England Journal of Medicine CUMULATIVE EFFECTS OF HIGH CHOLESTEROL LEVELS, HIGH BLOOD PRESSURE, AND CIGARETTE SMOKING ON CAROTID STENOSIS
CUMULATIVE EFFECTS OF HIGH CHOLESTEROL LEVELS, HIGH BLOOD PRESSURE, AND CIGARETTE SMOKING ON CAROTID STENOSIS PETER W.F. WILSON, M.D., JEFFREY M. HOEG, M.D., RALPH B. D AGOSTINO, PH.D., HALIT SILBERSHATZ,
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationCoronary heart disease (CHD) is the leading cause of
Serum Albumin and Risk of Myocardial Infarction and All-Cause Mortality in the Framingham Offspring Study Luc Djoussé, MD, DSc; Kenneth J. Rothman, DrPH; L. Adrienne Cupples, PhD; Daniel Levy, MD; R. Curtis
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationNIH Public Access Author Manuscript Metab Brain Dis. Author manuscript; available in PMC 2011 October 24.
NIH Public Access Author Manuscript Published in final edited form as: Metab Brain Dis. 2006 September ; 21(2-3): 235 240. doi:10.1007/s11011-006-9017-2. Risk factors for incident Alzheimer s disease in
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationORIGINAL CONTRIBUTION. Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
ORIGINAL CONTRIBUTION Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease Preliminary Results D. Larry Sparks, PhD; Marwan N. Sabbagh, MD; Donald J. Connor, PhD, PhD; Jean Lopez, MSN,
More informationHyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine
Hyperlipidemia in an Otherwise Healthy Theodore D Fraker, Jr, MD Professor of Medicine Orlando, Florida October 7-9, 2011 80-Year-Old Patient Primary Prevention Issues in the Elderly: Coronary artery disease
More informationThe New England Journal of Medicine PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR DEMENTIA AND ALZHEIMER S DISEASE. Subjects
PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR DEMENTIA AND ALZHEIMER S DISEASE SUDHA SESHADRI, M.D., ALEXA BEISER, PH.D., JACOB SELHUB, PH.D., PAUL F. JACQUES, SC.D., IRWIN H. ROSENBERG, M.D., RALPH B. D AGOSTINO,
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationBaldness and Coronary Heart Disease Rates in Men from the Framingham Study
A BRIEF ORIGINAL CONTRIBUTION Baldness and Coronary Heart Disease Rates in Men from the Framingham Study The authors assessed the relation between the extent and progression of baldness and coronary heart
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationThe Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationSection: Genetic Testing Last Reviewed Date: December Policy No: 05 Effective Date: March 1, 2014
Medical Policy Manual Topic: Apolipoprotein E for Risk Assessment and Management of Cardiovascular Disease Date of Origin: January 2013 Section: Genetic Testing Last Reviewed Date: December 2013 Policy
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationIN ADDITION TO THE WELL-DOCUmented
ORIGINAL CONTRIBUTION Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE 4 The Cardiovascular Health Study Cognition Study Fumiko Irie, MD, PhD, MPH; Annette L. Fitzpatrick, PhD;
More informationSUPPLEMENTARY APPENDIX
Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 23 million people and more than 100,000 cases of dementia SUPPLEMENTARY APPENDIX Supplementary Methods Newcastle
More informationORIGINAL INVESTIGATION. Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia
ORIGINAL INVESTIGATION Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia Annika Rosengren, MD, PhD; Ingmar Skoog, MD, PhD; Deborah Gustafson, PhD; Lars Wilhelmsen, MD,
More informationYong-Bum Kim, M.D., Kwang-Ho Lee, M.D., Soo-Joo Lee, M.D., Duk-L. Na, M.D., Soo-Jin Cho, M.D., Chin-Sang Chung, M.D., Won-Yong Lee M.D.
Usefulness of Apolipoprotein E 4 and Distribution of Petechial Hemorrhages in Differentiating between Cerebral Amyloid Angiopathy and Hypertensive Intracerebral Hemorrhage Yong-Bum Kim, M.D., Kwang-Ho
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAlthough the prevalence and incidence of type 2 diabetes mellitus
n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationORIGINAL INVESTIGATION. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women
The Impact of Mellitus on Mortality From All Causes and Coronary Heart Disease in Women 20 Years of Follow-up ORIGINAL INVESTIGATION Frank B. Hu, MD; Meir J. Stampfer, MD; Caren G. Solomon, MD; Simin Liu,
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationAnalyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne
Abstract Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins Peter Thorne A sample of adults participating in the first 7 months of visit 5 of the Atherosclerosis
More informationRisk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan
22 Risk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan Jun-Cheng Lin 1,2, Wen-Chuin Hsu 1, Hai-Pei Hsu 1,2, Hon-Chung Fung 1, and Sien-Tsong Chen 1 Abstract- Background: In Taiwan, next
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationCholesterol (blood, plasma, serum)
1 Cholesterol (blood, plasma, serum) 1 Name and description of analyte 1.1 Name of analyte Cholesterol (plasma; also blood, serum) 1.2 Alternative names 2,15-dimethyl-14-(1,5-dimethylhexyl)tetracyclo[8.7.0.0
More informationMetabolic syndrome is a constellation of cardiovascular
and Cognitive Decline in Elderly Latinos: Findings from the Sacramento Area Latino Study of Aging Study Kristine Yaffe, MD, wzk Mary Haan, DrPH, MPH, z Terri Blackwell, MA, # Elena Cherkasova, BA, Rachel
More informationthe U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations
Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,
More informationAssociation of statin use with risk of dementia: A meta-analysis of prospective cohort studies
bs_bs_banner Geriatr Gerontol Int 2013; 13: 817 824 REVIEW ARTICLE Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies Yu Song, 1 Hongwei Nie, 2 * Yong Xu, 1
More informationC-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationRegence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
Regence Medical Policy Manual Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Date of Origin: May 2013 Section: Genetic Testing Last Reviewed Date: June 2013
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri
More informationORIGINAL INVESTIGATION. Glycemic Index and Serum High-Density Lipoprotein Cholesterol Concentration Among US Adults
Glycemic Index and Serum High-Density Lipoprotein Cholesterol Concentration Among US Adults Earl S. Ford, MD; Simin Liu, MD ORIGINAL INVESTIGATION Background: Dietary glycemic index, an indicator of the
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationRecently reported clinical trials have provided strong
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions The Atherosclerosis Risk in Communities (ARIC)
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationSeparation of HDL Particles by Immunoprecipitation
Sun Diagnostics, LLC Separation of HDL Particles by Immunoprecipitation Rae-Anne Nguyen and John H. Contois 13 Introduction We all know that HDL cholesterol concentration is inversely associated with coronary
More informationObesity, diabetes and cognitive deficit: The Framingham Heart Study
Neurobiology of Aging 26S (2005) S11 S16 Obesity, diabetes and cognitive deficit: The Framingham Heart Study Merrill F. Elias a,b,, Penelope K. Elias a,b, Lisa M. Sullivan a,c, Philip A. Wolf d, Ralph
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationRosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,
More informationORIGINAL INVESTIGATION. Elevated Midlife Blood Pressure Increases Stroke Risk in Elderly Persons
Elevated Midlife Blood Increases Stroke Risk in Elderly Persons The Framingham Study ORIGINAL INVESTIGATION Sudha Seshadri, MD; Philip A. Wolf, MD; Alexa Beiser, PhD; Ramachandran S. Vasan, MD; Peter W.
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationDECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE
& DECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE Orhan Lepara¹*, Amina Valjevac¹, Azra Alajbegović², Asija Zaćiragić¹, Emina Nakaš-Ićindić¹ ¹ Institute of Physiology and Biochemistry,
More informationIntermittent claudication (IC) is a clinical manifestation of
Alcohol Consumption and Risk of Intermittent Claudication in the Framingham Heart Study Luc Djoussé, MD, MPH; Daniel Levy, MD; Joanne M. Murabito, MD, MS; L. Adrienne Cupples, PhD; R. Curtis Ellison, MD
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationSaturated fat- how long can you go/how low should you go?
Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationSerum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study
CLINICAL RESEARCH STUDY Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study Vidula Bhole, MD, MHSc, a Jee Woong J. Choi, a Sung Woo Kim, a Mary de Vera, MSc, a,b Hyon Choi, MD,
More informationORIGINAL CONTRIBUTION. Apolipoprotein E 4 and Age at Onset of Sporadic and Familial Alzheimer Disease in Caribbean Hispanics
ORIGINAL CONTRIBUTION Apolipoprotein E 4 and Age at Onset of Sporadic and Familial Alzheimer Disease in Caribbean Hispanics Lucia Olarte, BS; Nicole Schupf, PhD; Joseph H. Lee, DPH; Ming-Xin Tang, PhD;
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationValidity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease
Genetic Epidemiology 15:215 223 (1998) Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease G. Devi, 1,3 * K. Marder, 1,3 P.W. Schofield,
More information